Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.

The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.

Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.